US FDA grants Fast Track status for Pfizer-BioNTech’s combination vaccine
Pharmaceutical Technology
DECEMBER 11, 2022
The US Food and Drug Administration (FDA) has granted Fast Track designation for Pfizer and BioNTech’s messenger ribonucleic acid (mRNA)-based combination vaccine candidate against Covid-19 and influenza. The vaccine is intended to prevent two respiratory ailments through a single injection.
Let's personalize your content